Gevotroline Explained

Gevotroline (WY-47,384) is an atypical antipsychotic with a tricyclic structure which was under development for the treatment of schizophrenia by Wyeth-Ayerst.^{[1] [2] [3]} It acts as a balanced, modest affinity D₂ and 5-HT₂ receptor antagonist and also possesses high affinity for the sigma receptor.^{[4] [5] [6]} It was well tolerated and showed efficacy in phase II clinical trials but was never marketed.

See also

• Atypical antipsychotic
• Atiprosin
• Azepindole

Notes and References

1. Book: Triggle DJ . Dictionary of Pharmacological Agents . Chapman & Hall/CRC . Boca Raton . 1996 . 0-412-46630-9 .
2. Abou-Gharbia M, Moyer JA . Novel Antipyschotic Agents. Bristol JA . Annual Reports in Medicinal Chemistry . 25 . 1–10 . Academic Press . Boston . 1990 . 0-12-040525-3 . 10.1016/S0065-7743(08)61577-8 .
3. Book: Jackson DM, Mohell N . A Review of the Pharmacology of New Antipsychotic Drugs. Stone TW . CNS neurotransmitters and neuromodulators: dopamine . CRC Press . Boca Raton . 1996 . 0-8493-7632-7 . https://books.google.com/books?id=ObG24oxrivEC&q=gevotroline&pg=PA187.
4. Snyder SH, Largent BL . Receptor mechanisms in antipsychotic drug action: focus on sigma receptors . The Journal of Neuropsychiatry and Clinical Neurosciences . 1 . 1 . 7–15 . 1989 . 2577720 . 10.1176/jnp.1.1.7 .
5. Matheson GK, Guthrie D, Bauer C, Knowles A, White G, Ruston C . Sigma receptor ligands alter concentrations of corticosterone in plasma in the rat . Neuropharmacology . 30 . 1 . 79–87 . January 1991 . 1675451 . 10.1016/0028-3908(91)90046-E . 29702968 .
6. Gudelsky GA, Nash JF . Neuroendocrinological and neurochemical effects of sigma ligands . Neuropharmacology . 31 . 2 . 157–162 . February 1992 . 1348112 . 10.1016/0028-3908(92)90026-L . 36585024 .